SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

KLOXERATE GOLD DC

Intramammary suspension.

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Active substances:

Each 5.4g syringe contains:

Cloxacillin (as lecithin coated benzathine salt) 600mg

Ampicillin (as trihydrate) 300mg

Excipient(s):

For a full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Intramammary suspension.

An oily off-white suspension

4. CLINICAL PARTICULARS

4.1 Target species

Cattle

4.2 Indications for use, specifying the target species

Kloxerate Gold DC is formulated for use in the dairy cow at the point of drying off, that is, immediately after the last milking of the lactation in order to treat existing mastitis and to provide protection against further infections during the dry period.

Kloxerate Gold DC is active against both Gram-positive and Gram-negative organisms, which are associated with mastitis, and is effective against Streptococcus agalactiae and other Streptococcus species, Penicillin resistant and sensitive Staphylococci, Arcanobacterium spp, Escherichia coli and other susceptible Gram- negative bacteria.

4.3 Contraindications

None.

4.4 Special warnings for each Target Species

None known.

4.5 Special precautions for use

i. Special precautions for use in animals

When infusing heifers it is important that the syringe nozzle is not introduced into the teat. The recommended procedure is as follows:

The animal(s) should be properly restrained. The teats are cleaned and disinfected. The teat orifice is located and the nozzle of the syringe placed against it but NOT inserted. When the syringe plunger is depressed the antibiotic passes easily through the teat into the udder.

ii. Special precautions to be taken by the person administering the veterinary medicinal product to animals

Protective gloves should always be worn when infusing heifers, to avoid skin contact with the product.

Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross-reactions to cephalosporins and vice versa. Allergic reactions to these substances may occasionally be serious.

Sensitised individuals or those advised not to work with such preparations should not handle this product.

This product should be handled with great care to avoid exposure, taking all recommended precautions.

Should symptoms develop following exposure such as skin rash, medical advice should be sought. Swelling of the face, lips or eyes or difficulty with breathing are more serious symptoms and require urgent medical attention.

Wash hands after use.

4.6 Adverse reactions (frequency and seriousness)

None known.

4.7 Use during pregnancy, lactation or lay

The product is safe for use during pregnancy.

4.8 Interaction with other medicinal products and other forms of interaction

None known.

4.9 Amounts to be administered and administration route

For intramammary infusion in dairy cows and heifers.

Dry Off Therapy: After the final milking of a lactation, clean and disinfect the teats and introduce the contents of one tube into each quarter via the teat canal.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

Not applicable.

4.11 Withdrawal period(s)

Do not use in cows which have a short dry period.

Not intended for use within 49 days of calving.

Milk for human consumption may only be taken from 156 hours after calving. Should a cow calve earlier than 49 days after the last treatment, milk for human consumption may only be taken from 49 days plus 156 hours after the last treatment. Should a cow calve earlier than 49 days after treatment consult your veterinary surgeon.

In cows suffering from hypocalcaemia it may be necessary to withhold milk for a longer period than that stated above. In such cases milk should be withheld until the levels of antibiotics are below the maximum accepted residue levels, i.e. 0.03mcg/ml for cloxacillin and 0.004 mcg/ml for ampicillin.

Animals must not be slaughtered for human consumption during treatment. Cattle may be slaughtered for human consumption only after 28 days from the last treatment.

The product must not be used in the treatment of lactating cows. Should this occur milk should be discarded for 28 days, following which time milk should be tested until antibiotic can no longer be detected.

5. PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: Antibacterials for intramammary use, Beta-lactam antibacterials, penicillins, for intramammary use, Combinations of penicillins and/or beta-lactamase inhibitors.

ATCvet code: QJ51CR50

Kloxerate Gold DC contains ampicillin and cloxacillin both beta-lactam antibiotics, their structures containing the same beta-lactam ring and thiazolidine ring common to all penicillins.

Beta lactam antibiotics prevent the bacterial cell wall from forming by interfering with the final stage of peptidoglycan synthesis. They inhibit the activity of transpeptidase enzymes, which catalyse cross-linkage of the glycopeptide polymer units that form the cell wall. They exert a bactericidal action but cause lysis only of growing cells. The difference in susceptibility between Gram-positive and Gram-negative bacteria depends on differences in receptor sites, on the relative amount of peptidoglycan present, on the ability of drugs to penetrate the outer cell membrane of Gram-negative bacteria and on resistance to the different types of beta-lactamase enzymes produced by the bacteria.

Ampicillin has a high activity against both Gram-positive and Gram-negative bacteria but is inactivated by beta-lactamases.

Cloxacillin is relatively resistant to staphylococcal beta-lactamases but of lower activity than penicillin G against susceptible gram-positive bacteria and inactive against Gram-negative bacteria.

The combination of penicillinase-resistant penicillins, such as cloxacillin, with ampicillin, against common opportunist Gram-negative bacteria, has shown synergism in many cases.

Cloxacillin benzathine and ampicillin trihydrate in a long-acting base maintain effective antibacterial levels in the dry cow udder for up to 10 weeks and are non-irritant to udder tissue.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Aluminium distearate

Liquid paraffin

6.2 Incompatibilities

None known.

6.3 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.

6.4. Special precautions for storage

Do not store above 25^oC.

The syringe may only be used once.

Part-used syringes must be discarded.

6.5 Nature and composition of immediate packaging

Packs of 20 and 100 high-density polyethylene syringes, each syringe containing 5.4g of suspension.

Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary

medicinal products should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Zoetis UK Limited

5th Floor, 6 St. Andrew Street

London

EC4A 3AE

8. MARKETING AUTHORISATION NUMBER

Vm 42058/4201

9. DATE OF FIRST AUTHORISATION

06 June 1994

10. DATE OF REVISION OF THE TEXT

June 2015

Approved: 02 June 2015